These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2410195)

  • 21. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY; Nichols WW; Saldeen TG; Mehta JL
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation.
    Duboscq C; Genoud V; Parborell MF; Kordich LC
    Thromb Res; 1997 Jun; 86(6):505-13. PubMed ID: 9219330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for an active fibrinolytic system in normal human bone marrow.
    McWilliam NA; Robbie LA; Barelle CJ; Adey G; Prasad S; Bennett B; Booth NA
    Br J Haematol; 1996 Apr; 93(1):170-6. PubMed ID: 8611456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of hemostasis in ischemic cerebrovascular disease. III. Abnormalities in vascular plasminogen activators, antiactivators and alpha 2-antiplasmin.
    Mettinger KL; Egberg N
    Thromb Res; 1982 May; 26(3):203-10. PubMed ID: 6810498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of fibrin on the enhanced activation of plasminogen by urokinase and tissue plasminogen activator: role of cross-link.
    Takada A; Watahiki Y; Takada Y
    Thromb Res; 1986 Mar; 41(5):605-13. PubMed ID: 3083529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation.
    Fukao H; Ueshima S; Okada K; Yamamoto K; Matsuo T; Matsuo O
    Thromb Res; 1992 Oct; 68(1):57-65. PubMed ID: 1280377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Staphylokinase reduces plasmin formation by endogenous plasminogen activators.
    Jin T; Bokarewa M; Zhu Y; Tarkowski A
    Eur J Haematol; 2008 Jul; 81(1):8-17. PubMed ID: 18331597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinolytic properties of activated FXII.
    Braat EA; Dooijewaard G; Rijken DC
    Eur J Biochem; 1999 Aug; 263(3):904-11. PubMed ID: 10469157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tissue plasminogen activator (t-PA) in aqueous humor of patients with cataract].
    Kotschy M; Kałuzny J; Kaniasty M; Zekanowska E; Kropińska E
    Klin Oczna; 1996 Mar; 98(3):201-3. PubMed ID: 9019589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrinolysis activity promotes tumor invasiveness of B16 melanoma cell lines through a reconstituted gel matrix.
    Mimura K; Sueishi K; Yasunaga C; Tanaka K
    Invasion Metastasis; 1992; 12(1):24-34. PubMed ID: 1380952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
    Kojima T; Gando S; Morimoto Y; Mashio H; Goda Y; Kawahigashi H; Kemmotsu O
    Thromb Res; 2001 Dec; 104(5):301-7. PubMed ID: 11738071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
    Lucore CL; Sobel BE
    Circulation; 1988 Mar; 77(3):660-9. PubMed ID: 2449299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder.
    Sheth PM; Kahr WH; Haq MA; Veljkovic DK; Rivard GE; Hayward CP
    Thromb Haemost; 2003 Aug; 90(2):293-8. PubMed ID: 12888877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homozygous type I plasminogen deficiency.
    Mingers AM; Heimburger N; Zeitler P; Kreth HW; Schuster V
    Semin Thromb Hemost; 1997; 23(3):259-69. PubMed ID: 9255907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.